Lung fibrosis is a dysregulated or exaggerated tissue repair process resulting in the thickening or scarring of lung tissue. It involves the presence of sustained or repeated exposure to a stressor and intricate dynamics between several inflammatory and immune response cells, and the microenvironment of the alveolar-capillary region consisting of both immune and non-immune cells, and the lung interstitium. This AOP is applicable to a broad group of stressors of diverse properties e.g. metal dusts, pharmacological products, fibres, microorganisms, chemicals, including novel technology-enabled stressors such as nanomaterials. This AOP is referred to as AOP 173 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).
Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis
Working paper
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
30 June 2025193 Pages
-
Working paper30 June 2025250 Pages
-
30 June 2025329 Pages
-
Working paper30 June 2025270 Pages
-
Working paper26 June 202599 Pages
-
Working paper12 December 202367 Pages
Related publications
-
15 December 2025169 Pages
-
Report3 December 202594 Pages
-
30 June 2025193 Pages
-
Working paper30 June 2025250 Pages
-
30 June 2025329 Pages
-
Working paper30 June 2025270 Pages